SRRK Stock — Scholar Rock Holding Corporation: Cash, EV, Pipeline

Share price

$46.65

Market cap

$5,681.3M

Cash

$492.1M

Enterprise value

$5,385.4M

Balance sheet

Cash	$492.1M
Debt	$196.2M
Net cash	$295.9M
Enterprise value	$5,385.4M
Basic shares	121.6M shares
Fully diluted shares	137.5M shares
Fully diluted market cap	$6,413.6M
Cash per share	$4.05

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SRRK daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027	Apitegromab	Phase 3	Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2	—
Jan 28 - Mar 11	SRK-439	Phase 1	Healthy	—
Jul 13 - Aug 24	Apitegromab	Phase 2	Facioscapulohumeral Muscular Dystrophy; FSHD	—
Dec 13, 2028 - Jan 24, 2029	Apitegromab	Phase 2	Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

apitegromab

Phase 3 · Active Modality: monoclonal antibody (IV)

Target myostatin (pro- and latent forms)

Indications

spinal muscular atrophy (SMA) (Phase 3)

Catalysts

— 2026-09-30

Status note Phase 3 SAPPHIRE in SMA (October 2024). BLA submitted January 2025 (priority review); CRL September 2025; resubmitted; FDA accepted with September 30, 2026 PDUFA. Long-term extension ONYX ongoing. A subcutaneous formulation completed a Phase 1 study in healthy volunteers; further development activities ongoing, including planned FDA/EMA regulatory engagements following potential apitegromab approvals.

SRK-439

Phase 1 · Active Modality: monoclonal antibody (subcutaneous)

Target myostatin (pro- and latent forms)

Indications

Rare, severe, debilitating neuromuscular diseases (Phase 1)

Catalysts

— second half of 2026

Status note Subcutaneously administered anti-pro/latent myostatin antibody. Phase 1 study in healthy volunteers underway.

SRK-181

Phase 1 · Active Modality: monoclonal antibody

Target latent TGFβ1

Indications

Locally advanced or metastatic solid tumors resistant to anti-PD-(L)1 therapies (Phase 1)

Status note Phase 1 DRAGON trial in urothelial carcinoma, melanoma, NSCLC, ccRCC and head and neck SCC completed 2025. Phase 2-ready; company currently seeking partnerships.

SRK-373

Preclinical · Active Modality: monoclonal antibody

Target latent TGFβ1

Indications

Fibrotic diseases (Preclinical)

Status note Preclinical development. Company currently seeking partnerships.

SRK-256

Preclinical · Active Modality: monoclonal antibody

Target RGMc (hemojuvelin)

Indications

Iron-restricted anemias (Preclinical)

Status note Preclinical development. Company currently seeking partnerships.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Apitegromab
Lead indication	Spinal Muscular Atrophy
Lead phase	Phase 3
Active trials	4
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05626855	Phase 3	Active, not recruiting	Sponsor	SRRK	—	Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2	—
NCT07435129	Phase 2	Recruiting	Sponsor	SRRK	—	Facioscapulohumeral Muscular Dystrophy; FSHD	—
NCT07047144	Phase 2	Recruiting	Sponsor	SRRK	—	Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2	—
NCT07444294	Phase 1	Recruiting	Sponsor	SRRK	—	Healthy	—
NCT05737602	Not disclosed	Active, not recruiting	Collaborator	Massachusetts General Hospital	—	Von Hippel-Lindau Disease; Genetic Disorder	—
NCT04756245	Not disclosed	Recruiting	Collaborator	Wake Forest University	—	Exercise; Behavior; Loneliness	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Scholar Rock, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	200,000	+200,000	0.47%	2026-08-14
Sphera Biotech	94,265	no change	0.74%	2026-08-14
ADAR1 Capital Management	0	-407,273	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SRRK — Scholar Rock Holding Corporation

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders